Compositions and methods for treating cardiovascular disease
AssigneesThe Broad Institute, Inc., The General Hospital Corporation
InventorsChenhao Li, Martin Strazar, Ahmed M. T. Mohamed, Damian R. Plichta, Ramnik J. Xavier
Life of this patent
Estimating the term…
Abstract
The present disclosure includes compositions and methods for treating cardiovascular disease (CVD) (e.g., cholesterol related disorders, or diseases caused or characterized by increased levels of plasma triglycerides, plasma cholesterol, or serum C-reactive protein), or symptoms thereof. The disclosure also includes compositions and methods for lowering plasma triglycerides in a subject, lowering plasma cholesterol levels in a subject, and lowering serum C-reactive protein levels in a subject.
Claims20
A composition comprising or consisting of i) a CgT polypeptide or polynucleotide;
- ii) an Oscillibacter or Dysosmobacter IsmA polypeptide or polynucleotide;
- or iii) a combination of a CgT polypeptide or polynucleotide and an Oscillibacter or Dysosmobacter IsmA polypeptide or polynucleotide;
- and a pharmaceutically acceptable excipient.
A composition comprising an effective amount of an IsmA polypeptide having at least 85% amino acid sequence identity to a polypeptide encoded by Oscillibacter gene RJX3347_02204 or RJX3711_01778, or Dysosmobacter gene J115_02655 and an effective amount of an CgT polypeptide having at least 85%, 90%, or 95% amino acid sequence identity to a polypeptide encoded by Oscillibacter gene RJX3347_02251 or Dysosmobacter gene J115 17675.
A composition comprising or consisting of an isolated Oscillibacter species and an excipient.
A composition comprising or consisting of an isolated Oscillibacter species and an isolated Eubacterium species each expressing IsmA.
A recombinant microbial cell wherein the cell comprises a heterologous polynucleotide encoding an IsmA polypeptide.
An expression vector comprising a polynucleotide encoding an IsmA polypeptide or CgT polypeptide.
Dependencies are inferred from the claim text.